This dataset provides data for new prescription drugs introduced to market in California with a Wholesale Acquisition Cost (WAC) that exceeds the Medicare Part D specialty drug cost threshold. Prescription drug manufacturers submit information to HCAI within a specified time period after a drug is introduced to market. Key data elements include the National Drug Code (NDC) administered by the FDA, a narrative description of marketing and pricing plans, and WAC, among other information. Manufacturers may withhold information that is not in the public domain. Note that prescription drug manufacturers are able to submit new drug reports for a prior quarter at any time. Therefore, the data set may include additional new drug report(s) from previous quarter(s).

There are two types of New Drug data sets: Monthly and Annual. The Monthly data sets include the data in completed reports submitted by manufacturers for calendar year 2025, as of September 9, 2025. The Annual data sets include data in completed reports submitted by manufacturers for the specified year. The data sets may include reports that do not meet the specified minimum thresholds for reporting.

The program regulations are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/CTRx-Regulations-Text.pdf

The data format and file specifications are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/Format-and-File-Specifications-version-2.0-ada.pdf

DATA NOTES: Due to recent changes in Excel capabilities, it is not recommended that you save these files to .csv format. If you do, when importing back into Excel the leading zeros in the NDC number column will be dropped. If you need to save it into a different format other than .xlsx it must be .txt

The top U.S. pharmacy in 2024 by market share based on prescription drug revenue was CVS Health Corporation, followed by Walgreens Boots Alliance. CVS Health held over 25 percent of the prescription drug market revenue at that time. A significant increase in market share was reported for Cigna achieved through the acquisition of pharmacy benefit manager Express Scripts in August 2018. Before that, Cigna was mainly active in the insurance business and related products and services. CVS pharmaciesThe CVS Health Corporation is a health service company with locations all over the United States, Puerto Rico and Brazil. CVS Health comprises pharmacies, clinics and retail locations. According to recent estimates the number of CVS pharmacies has increased dramatically since 2005, however, with a downward tendency since 2021.Pharmaceutical and pharmacy marketThe U.S. has the largest single share of global pharmaceutical market revenues. The total number of prescriptions dispensed in the U.S. has increased in the last years, reaching around 6.7 billion medical prescriptions in 2022. Prescription drug expenditures have been increasing in value, while the share related to total U.S. health expenditures has remained stable in recent years. On the other hand, the pharmacy market recently saw some significant changes, especially with the growing impact of online pharmacies (mail-order pharmacies) worldwide.

The prescription delivery service market is evaluated to be sized at US$ 165.4 million in 2024. During the period from 2024 to 2034, the market is expected to progress at a solid clip, registering a CAGR of 5.7%. By 2034, the prescription delivery service market is anticipated to have reached a value of US$ 287.9 million.

Category-wise Outlook

Country-Wise Analysis

This statistic depicts a projection for the total prescription drug revenue worldwide from 2023 to 2030. In 2025, the industry is expected to generate *** trillion U.S. dollars in prescription drug revenue worldwide. Revenues are projected to exceed *** trillion U.S. dollars by 2030. There is an increasing growth, especially, in sales of so-called orphan drugs for the treatment of rare diseases.

In 2024, the top pharmacy benefit managers included Cigna, CVS Health, and OptumRx, to name the most important. Cigna had the largest share of the pharmacy benefit manager market in that year, holding ** percent of the market. Pharmacy benefit managers are an influential part of the prescription drug supply chain in the United States. Pharmacy benefit managers Pharmacy benefit managers are responsible for the operation and distribution of pharmaceuticals to patients and pharmacies. They are also responsible for the negotiation of rebates and processing of insurance claims from patients and pharmacies. Among pharmaceutical distributors in the U.S., chain stores distributed the largest value of pharmaceuticals recently. However, data suggests that pharmacy benefit managers have the highest gross profit among all actors in the U.S. drugs supply chain. Generic drugs Lately, the growth of the generic prescriptions volume in the U.S. market has remained fairly stable, with growth in all years. With stable growth in generics, the number of brand name medicines that were excluded from pharmacy benefit manager formularies recently had been on the rise. Generic drugs are useful to the consumer in that, in many cases, they provide a cheaper alternative to brand name drugs.

The U.S. Prescription Drugs Market size was valued at USD 461.33 USD Billion in 2023 and is projected to reach USD 755.46 USD Billion by 2032, exhibiting a CAGR of 7.3 % during the forecast period. Prescription drugs can only be purchased legally in America after the patient has been prescribed by a licensed pharmacist. It breaks it down into many types, which are Antibiotics, antidepressants, antipsychotics, Painkillers and many more. These drugs are recognized as being very effective in their workings and given in small dosages; the common populace cannot just buy these over the counter. Still, it includes FDA approval, the sources labelling and possible side effects which will have to be observed in the future. They are administered to control diseases that are chronic like high blood pressure, diabetes, depression, and a disease which is likely to be contracted. They have significant roles in the management of health and chronic illness and could potentially act as preventative measures against disease progress, and alleviate symptoms to improve patients’ lives. The benefits of the prescription are that it contains a therapeutic effect, results in minimizing hospital stays and leads to enhanced patient health in the long run. Recent developments include: June 2023: The U.S. FDA approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) manufactured by Boehringer Ingelheim International GmbH to improve blood sugar control in children ten years and older with type 2 diabetes., April 2022: Novartis AG announced the accelerated FDA approval of Vijoice (alpelisib) for treating adult and pediatric patients with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy., March 2021: Astellas Pharma Inc., announced the FDA approval of generic Myrbetriq (mirabegron) tablets for treating neurogenic detrusor overactivity (NDO) in pediatric patients aged three years and older.. Key drivers for this market are: Rising Approval of Orphan Drugs by Regulatory Agencies to Fuel Product Demand. Potential restraints include: High Costs of Specialty Prescription Drugs Compared to Over-the-Counter Drugs to Hamper Market Growth. Notable trends are: High Demand for Generic Drugs across the Country.

The U.S. Pharmaceutical Market size was valued at USD 4.1 billion in 2023 and is projected to reach USD 5.96 billion by 2032, exhibiting a CAGR of 5.48 % during the forecasts period. The U. S Pharmaceutical Industry therefore concerns the manufacturing and marketing of medicines and other therapeutic commodities. This sector is the one able to control, treat or even avoid illnesses and contributes to the improvement of health of the population. They are prescription drugs, over-the-counter drugs as well as biologics. There is an emerging pattern of personalized medicine evident in the increase of genomic and biotechnology plus digital health technologies such as telemedicine, health apps. It is also seeing some growth in areas such as specialty drugs and generics with large amounts being spent on research and development to meet the chronic disease and new health ailments. Global factors are also coming into play in this respect including changes in regulations and problems with pricing. Recent developments include: In December 2023, Pfizer received all regulatory approvals for the acquisition of Seagen. This initiative aims to bring commercial changes in the organization thereby creating a new space, the Pfizer Oncology Division to integrate oncology commercial and R&D operations from both the companies. , In January 2023, Sun Pharma announced the launch of a new drug, SEZABY for treating neonatal seizures in the U.S. This is the first USFDA-approved drug for term and pre-term babies. .

The Sweden Pharmaceutical Market Report Segments the Industry Into by ATC/Therapeutic Class (Cardiovascular System, Dermatological, Genito Urinary System and Sex Hormones, Anti-Infective for Systemic Use, Antineoplastic and Immunomodulating Agents, Musculoskeletal System, Nervous System, Respiratory System, and More), by Drug Type (Branded, Generic), and by Prescription Type (Prescription Drugs (Rx), Over the Counter (OTC) Drugs).

Snapshot img

US Pharmacy Market Size 2024-2028

The US pharmacy market size is forecast to increase by USD 90.8 billion at a CAGR of 3.14% between 2023 and 2028. In the dynamic market, several drivers, trends, and challenges shape the industry landscape. The aging population in the United States is a significant growth factor, leading to an increase in pharmaceutical sales. Pharmaceutical exports, biotechnology, biosimilars, biologics, antiretroviral drugs, and vaccines are significant contributors to the sector's growth. This demographic shift also necessitates the adoption of telepharmacy services to cater to the healthcare needs of an expanding elderly population. Another trend in the market is the digitization of electronic health records (EHRs). Additionally, rising pricing in pharmaceuticals and reimbursement pressures are predefined factors influencing market growth. Quality control and licensing are essential aspects of the market, with industry associations playing a crucial role in setting standards and ensuring regulatory compliance. According to recent survey results, retail stores and hospitals remain the key distribution channels for pharmaceuticals.

Request Free Sample

The market encompasses a wide range of healthcare products, including prescription medications, over-the-counter drugs, and health supplements. Pharmacists play a crucial role in ensuring the safe and effective use of these products by patients. With the increasing adoption of technology in healthcare, digital solutions have become essential components of modern pharmacy services. The growth of retail and hospital pharmacies is significantly influenced by the demand for OTC medications and generic medicines, with projections tied to GDP performance, especially during the April-January period when items like hydroxychloroquine became prominent in the market for medical goods. One significant trend in the market is the integration of technology into various aspects of pharmacy operations.

Furthermore, these digital pharmacies offer convenience and accessibility, allowing patients to order their prescriptions and over-the-counter medications from the comfort of their homes. National health services are increasingly adopting EHRs to improve patient care and streamline operations. EHRs enable pharmacists to access patients' medical histories, allergies, and medication lists, ensuring accurate and safe prescription dispensing. Technology is also transforming the production and distribution of healthcare products. API producers are leveraging digital solutions to improve the efficiency and quality of their manufacturing processes. The use of technology in the market is expected to continue growing, driven by the need for improved patient care, increased convenience, and cost savings.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  Prescription
  OTC


Ownership

  Pharmacy chain
  Independent


Type

  Retail pharmacy
  Hospital pharmacy
  Others


Geography

  US

By Product Insights

The Prescription segment is estimated to witness significant growth during the forecast period. Pharmaceutical businesses in the United States have leveraged the power of market segmentation to better understand consumer needs and preferences in the prescription sector. This approach allows companies to develop targeted marketing strategies, optimize inventory, and enhance overall customer satisfaction. One crucial aspect of prescription-based market segmentation involves categorizing customers based on their therapeutic requirements. These categories span various health conditions, including cardiovascular health, mental health, respiratory diseases, chronic pain management, and numerous others.

Furthermore, by segmenting the market, pharmacies ensure a comprehensive range of prescription medications for each category, enabling them to offer customized treatment solutions to their clients. The Internet's increasing penetration in the US has significantly influenced market segmentation in the pharmaceutical industry. The S-curve method, a popular analytical tool, helps visualize the growth patterns of various market segments. Exchange rates and representativeness are essential factors to consider when analyzing data from Global GCS data, a valuable resource, that provides insights into consumer behavior and trends within these segments. By staying abreast of market trends and consumer preferences, pharmacies can cater to the unique needs of their clientele, ultimately driving customer loyalty and business success.

Get a glance at the market share of various segments Request Free Sample

The prescription segment was valued at USD 425.20 billion in 2018 and showed a gradual incr

In 2024, the Japanese prescription drug market was valued at more than ** trillion Japanese yen, the historically highest value. The market size expanded by nearly four trillion yen throughout the past two decades.

Prescription Delivery Services Market size is set to expand from $ 165.86 Million in 2024 to $ 320.22 Million by 2034,CAGR of around 6.8% from 2025 to 2034.

Europe Pharmaceutical Drugs Market estimated to grow at a CAGR of 4.5%.

The Germany Pharmaceutical Market Report is Segmented by Therapeutic Category (Anti-Infectives, Gastrointestinal, and More) and Drug Type (Prescription Drugs and OTC Drugs), Molecule Type (Small-Molecule, Biologic, and Biosimilar), Route of Administration (Oral, Inhalation, and More), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More). The Market Sizes and Forecasts are Provided in Terms of Value (USD).

The Estonia Pharmaceutical Market is Segmented by Therapeutic Category (Anti-Infectives, Cardiovascular, Gastrointestinal, Anti-Diabetic, Respiratory, Dermatological, Musculoskeletal System, Nervous System, and Other Therapeutic Categories) and Drug Type (Prescription Drugs (Branded Drugs and Generic Drugs) and OTC Drugs). For Each Segment, The Market Size and Forecast are Provided in Terms of Value (USD).

Prescription Drugs Market size is expected to reach USD 2.47 Tn by 2032, from USD 1.34 Tn in 2025, exhibiting a CAGR of 9.1% during the forecast period

The Norway Pharmaceutical Market Report is Segmented by Therapeutic Class (Cardiovascular System, and More), Drug Type (Branded, Generic), Prescription Type (Prescription, Over-The-Counter), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Route of Administration (Oral, Parenteral, Topical, Others), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

The Denmark Pharmaceutical Market Report is Segmented by Therapeutic Category (Anti-Infectives, and More), Drug Type (Prescription Drugs, OTC Drugs), Formulation (Tablets, Capsules, Injectables, Others), Route of Administration (Oral, Parenteral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (Denmark). The Market Forecasts are Provided in Terms of Value (USD).

Pharmaceutical Market Outlook

In 2023, the global pharmaceutical market size was valued at approximately $1.25 trillion, and it is projected to reach $2.07 trillion by 2032, growing at a compound annual growth rate (CAGR) of 5.4%. This robust growth is fueled by an increasing global demand for advanced treatments and healthcare solutions. The pharmaceutical market is witnessing significant advancements in drug development and delivery technologies, alongside rising healthcare expenditures worldwide. Aging populations, especially in developed regions, and the growing prevalence of chronic diseases are pivotal factors driving the market expansion, subsequently contributing to the increased demand for both prescription and over-the-counter drugs.

The aging global population is a critical growth driver for the pharmaceutical market. As life expectancy increases globally, there is a corresponding rise in age-related health issues, such as cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders. This demographic shift necessitates ongoing innovation and production in the pharmaceutical industry to address the unique healthcare needs of an older population. Furthermore, with the advancement in medical sciences, there is a higher emphasis on personalized medicine, which tailors treatment plans to individual genetic makeups, thus boosting demand for specialized pharmaceuticals and biologics. This personalized approach not only improves patient outcomes but also enhances the overall efficacy of therapies, further propelling market growth.

Technological advancements in drug discovery and development are also pivotal in driving the pharmaceutical market. The integration of artificial intelligence and machine learning with pharmaceutical research has significantly expedited the drug discovery process, reducing the time and cost associated with bringing new drugs to market. These technologies enable the analysis of vast datasets to identify potential drug candidates more efficiently, thereby accelerating the development pipeline. Additionally, innovations in biologics and biosimilars have opened new avenues for treating complex conditions, such as autoimmune diseases and cancers, which were previously difficult to manage with traditional pharmaceuticals. As such, investment in R&D continues to be a cornerstone of growth within the pharmaceutical sector.

Another growth factor is the increasing global focus on preventive healthcare and wellness. With rising awareness of the importance of maintaining health to avoid chronic diseases, consumers are more inclined towards preventive measures, including vaccinations and health supplements, which fall under the pharmaceutical umbrella. Moreover, public health initiatives and policies aimed at enhancing healthcare access in emerging economies have led to increased pharmaceutical consumption. These initiatives are often supported by governmental and non-governmental organizations striving to improve healthcare infrastructure and accessibility. Consequently, as access to healthcare expands, so does the demand for pharmaceuticals, bolstering market growth.

The Pharma and Health Care sectors are intricately linked, with pharmaceutical advancements playing a crucial role in enhancing healthcare outcomes. The integration of cutting-edge pharmaceutical innovations into healthcare systems has led to more effective treatment protocols and improved patient care. As the demand for personalized and precision medicine grows, the collaboration between pharma companies and healthcare providers becomes even more essential. This synergy not only facilitates the development of new therapies but also ensures that these treatments are accessible to patients who need them most. Moreover, the focus on preventive healthcare within the pharmaceutical industry aligns with broader healthcare goals of reducing disease prevalence and improving public health.

Regionally, North America remains a dominant force in the pharmaceutical market, owing to high healthcare spending, advanced technology adoption, and strong R&D initiatives. However, the Asia Pacific region is witnessing the fastest growth, driven by large population bases, increasing income levels, and improving healthcare infrastructure. Countries like China and India are becoming significant players, with their expanding generic drug markets. Europe continues to be a strong market for pharmaceuticals due to its well-established healthcare systems and regulatory frameworks. Meanwhile, regions such as Latin America and the Middle East &

Prescription Price Transparency Tools Market Outlook

According to our latest research, the global prescription price transparency tools market size reached USD 1.42 billion in 2024, with a robust compound annual growth rate (CAGR) of 16.7% projected from 2025 to 2033. By the end of 2033, the market is expected to attain a value of USD 5.08 billion, driven by increasing regulatory mandates, the rising demand for cost-effective healthcare, and the growing adoption of digital health solutions worldwide. The primary growth factor is the intensifying need among patients, providers, and payers for real-time access to prescription drug pricing information, which is transforming the healthcare ecosystem by enhancing transparency and empowering informed decision-making.

One of the most significant growth factors for the prescription price transparency tools market is the escalating healthcare expenditure and the persistent rise in out-of-pocket costs for prescription medications. Patients are increasingly burdened by high drug prices, leading to medication non-adherence and poor health outcomes. Transparency tools help address this challenge by providing real-time, accurate pricing information, enabling patients to compare medication costs across pharmacies, insurance plans, and discount programs. The integration of these tools within electronic health record (EHR) systems and pharmacy benefit management (PBM) platforms is further amplifying their adoption. As healthcare systems globally shift toward value-based care models, the demand for solutions that promote price transparency and cost containment is expected to accelerate, fueling market growth.

Another critical driver is the evolving regulatory landscape, particularly in developed markets such as the United States and Europe. Governments and regulatory authorities are implementing policies that mandate healthcare providers and insurers to disclose drug pricing information to patients at the point of care. For instance, the Centers for Medicare & Medicaid Services (CMS) in the US has introduced rules requiring the use of real-time benefit tools (RTBTs) to provide patients with personalized out-of-pocket cost information before prescriptions are filled. These regulations are compelling healthcare organizations to invest in advanced transparency solutions, thereby expanding the market. Additionally, the growing emphasis on digital health transformation and the proliferation of telemedicine are further supporting the widespread deployment of prescription price transparency tools.

Technological advancements are also playing a pivotal role in shaping the prescription price transparency tools market. The integration of artificial intelligence (AI), machine learning, and big data analytics into these platforms is enhancing their predictive capabilities and delivering more personalized, actionable insights to users. Cloud-based deployment models are gaining traction due to their scalability, flexibility, and ease of integration with existing healthcare IT infrastructure. Moreover, the increasing collaboration between technology vendors, healthcare providers, and payers is fostering innovation and accelerating the development of user-friendly, interoperable solutions. As the healthcare industry continues to embrace digitalization, the adoption of sophisticated prescription price transparency tools is expected to surge, driving sustained market expansion.

From a regional perspective, North America currently dominates the prescription price transparency tools market, accounting for the largest share in 2024, followed by Europe and Asia Pacific. The strong presence of key market players, supportive regulatory frameworks, and high healthcare expenditure contribute to the region's leadership. However, Asia Pacific is emerging as a lucrative market, propelled by rapid digital health adoption, rising healthcare awareness, and government initiatives aimed at improving medication affordability. Latin America and the Middle East & Africa are also witnessing increased adoption, albeit at a slower pace, due to growing investments in healthcare infrastructure and digital health technologies. As these regions continue to evolve, the global landscape of prescription price transparency tools is expected to become more diversified and competitive.

Component Analysis

The component segment of the prescription price transparency tools market is bifurcated i

e-Prescription Market Outlook

The global e-prescription market size was valued at approximately USD 1.5 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 22.1% from 2024 to 2032, reaching an estimated USD 8.8 billion by the end of the forecast period. This burgeoning growth is largely driven by the increasing push towards digitalization in healthcare systems, alongside the need to improve patient safety and prescription accuracy. Other significant growth factors include governmental initiatives to reduce medication errors and enhance the integration of healthcare systems, which together create a formidable landscape for the proliferation of e-prescribing technologies.

One of the primary growth drivers for the e-prescription market is the rising incidence of medication errors, which can lead to adverse drug events (ADEs). These incidents have necessitated the need for more robust, reliable, and error-free prescription methods. E-prescribing minimizes the risk of errors compared to traditional handwritten prescriptions, as it automatically checks for drug interactions, allergies, and correct dosages. Consequently, healthcare providers are increasingly turning to e-prescription systems as a means to not only mitigate risks but also to enhance overall patient care. The integration of advanced technologies such as Artificial Intelligence (AI) and machine learning into e-prescription systems further enhances their capabilities, making them indispensable tools in modern healthcare.

Additionally, government mandates and incentives are playing a vital role in the market growth of e-prescriptions. In many developed countries, regulatory bodies have either mandated the use of e-prescriptions or provided significant incentives for healthcare systems that adopt these technologies. For instance, in the United States, the Medicare Electronic Prescribing Incentive Program offers financial incentives for the adoption and meaningful use of e-prescription systems. Similar initiatives in the European Union and other parts of the world are accelerating the adoption rate, highlighting the role of policy in market expansion. This legislative support not only boosts the initial uptake but also ensures sustained use of e-prescription systems as healthcare providers strive to comply with evolving regulatory standards.

The increasing prevalence of chronic diseases is another significant contributor to the market's growth. Chronic conditions such as diabetes, hypertension, and cardiovascular diseases require ongoing medication management, which in turn drives the demand for efficient and reliable prescription management systems. E-prescriptions facilitate easier and more effective management of medication regimens, thus improving adherence and outcomes for chronic disease patients. Furthermore, the convenience and efficiency associated with e-prescriptions are persuading more healthcare institutions to integrate these systems, thereby broadening their application and further fueling market expansion.

The role of Clinical ePrescribing Analytics is becoming increasingly crucial in the e-prescription market. By leveraging data-driven insights, healthcare providers can optimize prescribing practices, enhance patient outcomes, and reduce medication errors. These analytics tools allow for the monitoring of prescription patterns, helping to identify trends and potential issues before they escalate. As the healthcare industry continues to embrace digital transformation, the integration of Clinical ePrescribing Analytics into e-prescription systems is poised to drive significant improvements in medication management and patient safety. This capability not only supports healthcare providers in making informed decisions but also aligns with broader efforts to enhance the quality and efficiency of care delivery.

Regionally, North America holds a significant share of the global e-prescription market, primarily due to the early adoption of advanced healthcare technologies and supportive government policies. The region's market is characterized by a high penetration rate of electronic health records (EHRs) and a robust IT infrastructure, which collectively bolster the adoption of e-prescribing systems. Europe follows closely, with increasing investments in healthcare IT and a strong focus on patient safety driving the market. The Asia Pacific region is expected to witness the highest growth rate due to rising healthcare spending, improving technology infrastructure, and heightened awareness of digital healthcare